undamentalytics Newsletter
Sign in

Biocryst Pharmaceuticals Inc (BCRX) stock

Add to watchlist

Add holding +

NASDAQ: BCRX Nasdaq Biotechnology Next results ~November 4, 2026

B Fundamentals grade

Biocryst Pharmaceuticals Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: after-tax interest is 63% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

Price vs value

Under review: after-tax interest is 63% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy. We'll show the comparison once resolved.

Biocryst Pharmaceuticals Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Biocryst Pharmaceuticals files

Where Biocryst Pharmaceuticals stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $941m, up 68.7% on a year earlier, slower than the 75.9% growth a quarter earlier. Free-cash-flow margin rose to 39.7% from 2.8% a year earlier. Operating margin narrowed to -33.3% from 9.7%. The diluted share count is up 11.4% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 5 financial-health checks.

Our model value for Biocryst Pharmaceuticals is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Biocryst Pharmaceuticals Inc's trailing-twelve-month revenue grew 68.7% year on year, with a free-cash-flow margin of 39.7%. Where it stands out: free-cash-flow margin of 39.7% ranks 12 of 176 biotechnology companies we cover. Where it lags: long-term debt as % of assets of 70.9% ranks 73 of 78 biotechnology companies we cover.

Our discounted-cash-flow model values the business at ~$14 per share in the base case (~$10–$18 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 2269.0% while net income fell 977.2%: a 3246pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 68.7% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Strong cash generation. 39.7% of revenue turned into free cash flow, against a median of -145.4% for biotechnology companies we cover.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Growth slowing. The growth rate is 7.2 points lower than a quarter earlier.
  • Loss-making. Operating margin is -33.3%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 43.0 points on a year ago.
  • Share dilution. Diluted shares rose 11.4% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 48% and a beta of 0.7 against the S&P 500.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 70.9% ranks 73 of 78 biotechnology companies we cover (median 20.6%).

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
$0.35 against an average estimate of $0.23: beat by 49.4%
Revenue
$218m, up 33.6% on a year earlier
Share reaction
+3.1% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Guidance given
ORLADEYO revenue $625m to $645m (full year 2026); total revenue $690m to $715m (full year 2026)
Next report
November 4, 2026; average EPS estimate $0.12

Biocryst Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.8%
  • 1 week+5.7%
  • 1 month+4.8%
  • This year+5.8%
  • 1 year+24.9%
  • 5 years-26.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$941M
Operating margin
-33.3%
Net margin
-40.9%
EPS (TTM, diluted)
$-1.63

Growth

Revenue growth
+68.7%
Change in growth rate
−7.2 pts
Share count change
+11.4%

Cash

Free cash flow (TTM)
$373M
FCF margin
39.7%
Stock pay % of revenue
7.8%

Earnings

Last results
August 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Biocryst Pharmaceuticals Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: held for review: after-tax interest is 63% of the cash flow left for shareholders; our flat discount rate doesn't yet reflect debt this heavy.

Our value per share comes from a discounted-cash-flow model of Biocryst Pharmaceuticals Inc's free cash flow after stock-based pay ( $154M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$10.32$6.33$4.91$8.07$3.45$7.45$13.85$11.48$5.99$7.52$7.80$8.25
Market value$752m$467m$415m$833m$399m$1.2bn$2.5bn$2.1bn$1.2bn$1.6bn$1.7bn$2.0bn
+ Net debt (− = net cash)$29m$29m$1m$32m−$35m−$120m−$206m−$73m$193m$210m−$90m$240m
Enterprise value$781m$496m$416m$865m$364m$1.1bn$2.3bn$2.1bn$1.3bn$1.8bn$1.6bn$2.2bn
Multiples
Price / sales 15.6x17.7x16.5x40.3x8.2x70.0x15.8x7.9x3.5x3.4x1.9x2.1x
Price / earnings ——————————6.5x—
Price / free cash flow ——————————4.9x5.2x
EV / EBITDA ——————————4.7x—

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

46 /100

Moderate moat

How hard Biocryst Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Cash operating profit has been a median 16.6% of total assets over 7 years.

  • Pricing power 19 / 20

    Gross margin has been a median 97.5%, moving by 2.8 percentage points (standard deviation) across 7 years.

  • Durability 10 / 20

    Operating margin has been a median -119.1%; its worst year was -1024.5%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 2 of 10 years, at a median -111.5% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 69.8% over five years; stock-based pay has been a median 23.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (51 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, before the open. Analysts expect revenue of $166m and EPS of $0.12 (range $0.10 to $0.13) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.75 +18% $710m −19%
Next $0.82 +10% $736m +4%

Next year's EPS estimate has moved −17.5% in 90 days, across 2 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +13.6% on 90 days ago. In the last 30 days, 1 analyst raised Biocryst Pharmaceuticals Inc's forecast and 1 cut it.

Consensus EPS forecast Biocryst Pharmaceuticals Inc, last 90 days
$0.60 $0.70 $0.80 $0.90 $1.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.66 Current fiscal year, 60 days ago: $0.74 Current fiscal year, 30 days ago: $0.74 Current fiscal year, 7 days ago: $0.74 Current fiscal year, Now: $0.75 $0.75 Next fiscal year, 90 days ago: $1.00 Next fiscal year, 60 days ago: $0.94 Next fiscal year, 30 days ago: $0.94 Next fiscal year, 7 days ago: $0.94 Next fiscal year, Now: $0.82 $0.82

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.66$1.00
60 days ago $0.74$0.94
30 days ago $0.74$0.94
7 days ago $0.74$0.94
Now $0.75$0.82

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.23 $0.35 +49.4%
Mar 2026 $0.11 $0.14 +27.7%
Dec 2025 $0.07 $0.21 +197.6%
Sept 2025 $0.07 $0.16 +125.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026
  • total revenue full year 2026 $690m to $715m Raised
    “The company raised the full year 2026 total revenue outlook, including RAPIVAB ® (peramivir injection) and revenue from the licensing of navenibart European rights, to $690 million to $715 million.” source
  • ORLADEYO revenue full year 2026 $625m to $645m Maintained
    “The company maintained its outlook for full year 2026 global net ORLADEYO revenue of $625 million to $645 million.” source
  • non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs full year 2026 $420m to $440m Non-GAAP
    “In June, the company improved its outlook for full year 2026 non-GAAP operating expenses, excluding stock-based compensation, restructuring, and transaction-related costs, to $420 million to $440 million, due to the announced plans to discontinue internal discovery programs and close the Birmingham facility.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Biocryst Pharmaceuticals Inc's revenue by -13.8% next year and +11.1% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (-23.1%, weight 33%) , management guidance (-23.9%, weight 40%) and the company's own record (+13.0%, weight 27%) . How the weights are set.

Analyst recommendations

11 analysts, Oct 2026
Buy982%
Hold218%
Sell00%

Monthly trend

  1. Oct 202627211
  2. Sep 202627211
  3. Aug 202637111
  4. Jul 202637111

Counts of recommendations published by analysts covering Biocryst Pharmaceuticals Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
10.5%
of tradable shares
Days to cover
4.97
at average volume
Short interest, 1 month
−24%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.3%
of shares
Employees
435
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +12.7%

$7.32 on October 31, 2025 to $8.25

ThenNowEffect
Revenue (last 12 months) $558m $941m +68.7%
P/S multiple 2.8x 2.1x −25.6%
Share count 212m 237m −10.3%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years +36.6%

$6.04 on November 3, 2023 to $8.25

ThenNowEffect
Revenue (last 12 months) $307m $941m +206.7%
P/S multiple 3.7x 2.1x −43.9%
Share count 188m 237m −20.7%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
BCRX+86%−17%−48%+26%+4%+6%
Industry peers (median)−36%−57%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
BCRX67%67%33%50%50%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
BCRX−37%−60%−58%−46%−43%−31%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 85% from December 21, 2015 to November 14, 2019. Getting back needed a 585% gain, reached on February 1, 2021, 445 days after the low.

Price behaviour

52-week range
$6.24 – $11.11
From 52-week high
−25.7%
vs 50-day average
−4.1%
vs 200-day average
−5.7%
Volatility (1 year)
48%
Beta vs S&P 500
0.65

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±8.4%
After a week
6 up, 6 down
typical move ±7.9%
After a month
8 up, 4 down
typical move ±11.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 +3.1% −0.4% +17.4% +11.9%
May 6, 2026 −1.4% +1.1% +6.3% −6.9%
February 26, 2026 +15.9% −1.0% +12.6% +23.6%
January 12, 2026 −8.8% 0.0% −9.9% −7.6%
November 3, 2025 −7.7% −1.0% −1.6% +7.2%
October 14, 2025 −3.3% +0.3% −0.7% +2.0%
August 4, 2025 +5.2% +1.0% +3.1% +4.3%
May 5, 2025 +15.0% −1.4% +15.8% +23.6%
February 24, 2025 −10.1% −1.0% −7.3% −12.4%
January 10, 2025 −1.5% −1.4% −7.5% +11.7%
November 4, 2024 −16.3% +1.0% −2.8% −13.0%
August 5, 2024 +12.1% −2.0% +10.1% +17.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Biocryst Pharmaceuticals Inc in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Biocryst Pharmaceuticals Inc
$0 $500M $1B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $317.6M Revenue (TTM), FY23 Q4: $331.4M Revenue (TTM), FY24 Q1: $355.4M Revenue (TTM), FY24 Q2: $382.2M Revenue (TTM), FY24 Q3: $412.6M Revenue (TTM), FY24 Q4: $450.7M Revenue (TTM), FY25 Q1: $503.5M Revenue (TTM), FY25 Q2: $557.5M Revenue (TTM), FY25 Q3: $599.8M Revenue (TTM), FY25 Q4: $874.8M Revenue (TTM), FY26 Q1: $885.7M Revenue (TTM), FY26 Q2: $940.6M $940.6M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $317.6M
FY23 Q4 $331.4M
FY24 Q1 $355.4M
FY24 Q2 $382.2M
FY24 Q3 $412.6M
FY24 Q4 $450.7M
FY25 Q1 $503.5M
FY25 Q2 $557.5M
FY25 Q3 $599.8M
FY25 Q4 $874.8M
FY26 Q1 $885.7M
FY26 Q2 $940.6M
Revenue growth, TTM YoY Biocryst Pharmaceuticals Inc
0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 33.2% Revenue growth, TTM YoY, FY23 Q4: 22.4% Revenue growth, TTM YoY, FY24 Q1: 22.7% Revenue growth, TTM YoY, FY24 Q2: 24.7% Revenue growth, TTM YoY, FY24 Q3: 29.9% Revenue growth, TTM YoY, FY24 Q4: 36.0% Revenue growth, TTM YoY, FY25 Q1: 41.7% Revenue growth, TTM YoY, FY25 Q2: 45.9% Revenue growth, TTM YoY, FY25 Q3: 45.4% Revenue growth, TTM YoY, FY25 Q4: 94.1% Revenue growth, TTM YoY, FY26 Q1: 75.9% Revenue growth, TTM YoY, FY26 Q2: 68.7% 68.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 33.2%
FY23 Q4 22.4%
FY24 Q1 22.7%
FY24 Q2 24.7%
FY24 Q3 29.9%
FY24 Q4 36.0%
FY25 Q1 41.7%
FY25 Q2 45.9%
FY25 Q3 45.4%
FY25 Q4 94.1%
FY26 Q1 75.9%
FY26 Q2 68.7%
Operating margin (TTM) Biocryst Pharmaceuticals Inc
-50% 0% 50% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -33.8% Operating margin (TTM), FY23 Q4: -31.3% Operating margin (TTM), FY24 Q1: -25.3% Operating margin (TTM), FY24 Q2: -15.8% Operating margin (TTM), FY24 Q3: -9.9% Operating margin (TTM), FY24 Q4: -0.6% Operating margin (TTM), FY25 Q1: 6.6% Operating margin (TTM), FY25 Q2: 9.7% Operating margin (TTM), FY25 Q3: 12.7% Operating margin (TTM), FY25 Q4: 39.0% Operating margin (TTM), FY26 Q1: -43.1% Operating margin (TTM), FY26 Q2: -33.3% -33.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -33.8%
FY23 Q4 -31.3%
FY24 Q1 -25.3%
FY24 Q2 -15.8%
FY24 Q3 -9.9%
FY24 Q4 -0.6%
FY25 Q1 6.6%
FY25 Q2 9.7%
FY25 Q3 12.7%
FY25 Q4 39.0%
FY26 Q1 -43.1%
FY26 Q2 -33.3%
FCF margin (TTM) Biocryst Pharmaceuticals Inc
-40% -20% 0% 20% 40% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -35.3% FCF margin (TTM), FY23 Q4: -29.4% FCF margin (TTM), FY24 Q1: -29.1% FCF margin (TTM), FY24 Q2: -22.4% FCF margin (TTM), FY24 Q3: -13.7% FCF margin (TTM), FY24 Q4: -11.8% FCF margin (TTM), FY25 Q1: -5.3% FCF margin (TTM), FY25 Q2: 2.8% FCF margin (TTM), FY25 Q3: 8.0% FCF margin (TTM), FY25 Q4: 39.4% FCF margin (TTM), FY26 Q1: 35.0% FCF margin (TTM), FY26 Q2: 39.7% 39.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -35.3%
FY23 Q4 -29.4%
FY24 Q1 -29.1%
FY24 Q2 -22.4%
FY24 Q3 -13.7%
FY24 Q4 -11.8%
FY25 Q1 -5.3%
FY25 Q2 2.8%
FY25 Q3 8.0%
FY25 Q4 39.4%
FY26 Q1 35.0%
FY26 Q2 39.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Biocryst Pharmaceuticals took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $875M
  2. Cost of revenue $19.1M · 2.2%
  3. Gross profit $856M · 97.8%
  4. Research and development $166M · 19.0%
  5. Selling, general and admin $349M · 39.9%
  6. Operating income $341M · 39.0%
  7. Interest and other $73.6M · 8.4%
  8. Net income $264M · 30.2%

Shares of revenue. Source: Biocryst Pharmaceuticals's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 75 62 20 26 17 14 48 26 25 21 49 18 157 271 331 451 875 941
Gross profit 70 62 — — — — — 24 24 — 45 16 150 264 327 438 856 920
EBITDA — −32 −49 −33 −30 −46 −39 −48 −57 −93 −99 −174 −177 −147 −102 −1 342 −311
Operating income −14 −34 −50 −34 −31 −46 −39 −49 −57 −94 −99 −175 −178 −148 −104 −3 341 −313
Net income −13 −34 −57 −39 −30 −45 −43 −55 −66 −101 −109 −183 −184 −247 −227 −89 264 −385
Diluted EPS −$0.35 −$0.76 −$1.26 −$0.79 −$0.55 −$0.68 −$0.59 −$0.75 −$0.78 −$0.98 −$940.00 −$1.09 −$1.03 −$1.33 −$1.18 −$0.43 $1.21 −$1.63
Growth (year on year)
Revenue — −16.4% −68.5% +33.9% −34.1% −21.5% +254.6% −45.4% −4.4% −18.0% +136.5% −63.5% +782.4% +72.3% +22.4% +36.0% +94.1% +68.7%
EBITDA — — — — — — — — — — — — — — — — — −661.4%
Operating income — — — — — — — — — — — — — — — — — −677.8%
Margins
Gross margin 93.9% 99.9% — — — — — 91.3% 95.5% — 92.4% 91.3% 95.4% 97.6% 98.6% 97.3% 97.8% 97.8%
EBITDA margin — −51.4% −247.9% −126.5% −175.5% −335.1% −81.4% −182.6% −225.2% −452.5% −202.2% −976.9% −112.6% −54.3% −30.8% −0.3% 39.1% −33.1%
Operating margin −18.4% −55.1% −252.4% −128.9% −177.2% −336.4% −81.7% −184.4% −227.9% −456.2% −203.7% −981.1% −113.1% −54.8% −31.3% −0.6% 39.0% −33.3%
Net margin −18.0% −54.3% −289.9% −148.6% −173.7% −332.1% −89.1% −209.3% −261.2% −490.3% −223.0% <−999% −117.1% −91.2% −68.4% −19.7% 30.2% −40.9%
Free-cash-flow margin −22.6% −46.3% −164.5% −142.7% −153.3% −284.1% −37.8% −222.8% −164.7% −450.0% −184.1% −761.4% −92.0% −60.3% −29.4% −11.8% 39.4% 39.7%
Cash flow
Cash from operations −16 −29 −32 −37 −27 −39 −13 −53 −41 −93 −90 −135 −142 −162 −95 −52 347 376
Capital spending 1 0 0 0 0 0 5 5 0 0 0 1 2 1 2 1 2 3
Free cash flow −17 −29 −32 −38 −27 −39 −18 −59 −41 −93 −90 −136 −145 −163 −97 −53 345 373
Stock-based pay 6 6 5 4 4 10 10 8 13 9 18 15 35 45 56 65 85 73
Free cash flow after stock pay −22 −35 −37 −42 −31 −49 −28 −67 −54 −102 −108 −150 −179 −208 −153 −119 260 300
Balance sheet
Cash 41 14 16 21 21 55 29 22 50 27 114 272 504 305 111 105 90 155
Total debt 0 0 30 30 30 60 58 51 52 59 80 153 298 232 303 315 0 395
Net debt (negative = net cash) −41 −14 14 9 9 5 29 29 1 32 −35 −120 −206 −73 193 210 −90 240
Diluted shares — — — 49m 55m 67m 73m 74m 84m 103m 116m 167m 179m 186m 192m 207m 219m 237m
Returned to shareholders
Buybacks 0 0 0 — — — — — — — — — — — — — — —
Total returned 0 0 0 — — — — — — — — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 5 checks passed · June 30, 2026
What it owns · $558m
Short-term assets $485mLonger-term assets $73m
What it owes, and who funded it · $1.0bn
Short-term liabilities $209mLonger-term liabilities $803mShareholders' equity $-454m
  • Short-term assets cover short-term liabilities $485m of assets due within a year against $209m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $485m short-term assets against $803m of longer-dated liabilities.
  • More cash than debt $155m of cash against $395m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $376m of operating cash flow against $395m of debt.
  • Operating profit covers interest at least five times over Operating income of −$313m against $75m of interest.

From Biocryst Pharmaceuticals Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+11.4%
year over year
R&D spending
21.0%
of revenue
Sales & admin spending
35.9%
of revenue
Days sales outstanding
43 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated BCRX BBIO KNSA IONS LEGN ASND Median
Revenue, last 12 months $941m $946m $946m $874m $1.0bn $814m $56m
Revenue growth, last 12 months 68.7% 167.3% 58.2% −7.4% 64.0% 106.9% 12.6%
Revenue growth, 3-year average 45.3% 364.6% 56.1% 11.5% — — 13.7%
Revenue growth, latest quarter 33.6% 192.6% 58.1% −40.7% — — 10.2%
Gross margin 97.8% 94.3% 90.2% 98.2% 61.4% 86.8% 82.9%
Operating margin −33.3% −38.5% 13.8% −68.0% −13.3% −18.9% −189.4%
Operating margin, 3-year average −13.1% −153.6% 4.4% −47.0% — <−999% −363.5%
Net margin −40.9% −59.8% 11.6% −64.7% −28.8% −31.7% −169.8%
Cash from operations / revenue 40.0% −39.0% 21.0% −56.8% −9.7% 7.5% −168.0%
Free-cash-flow margin 39.7% −39.1% 20.8% −64.2% −12.5% 7.5% −162.4%
Free-cash-flow margin, 3-year average 6.7% −137.4% 13.6% −46.3% — <−999% −310.0%
Stock pay / revenue 7.8% 16.1% 4.8% 18.7% — 16.1% 20.0%
Change in share count 11.4% 2.4% 8.5% −2.8% 0.8% 4.7% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 68.7% 12.6% 48 of 172
Change in growth rate Growth -7.2pp -0.1pp 109 of 172
Gross margin Profitability 97.8% 82.4% 7 of 75
Operating margin Profitability -33.3% -189.4% 56 of 175
Net margin Profitability -40.9% -157.3% 60 of 180
Free-cash-flow margin Cash generation 39.7% -145.4% 12 of 176
Stock pay as % of revenue Cash generation 7.8% 19.2% 48 of 179
Long-term debt as % of assets Balance sheet 70.9% 20.6% 73 of 78
Change in share count Balance sheet 11.4% 7.9% 94 of 156
Days sales outstanding Balance sheet 43 days 75 days 22 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Products $623M ▲ 40.8%
ORLADEYO $602M ▲ 37.5%
License and Other Revenues $252M ▲ 3028.9%
Licenses $244M —
Other Income From Contract With Customer $29M ▲ 122.3%
Collaborative and Other Research and Development $7.7M ▼ 4.2%

These categories overlap or exclude eliminations, so shares aren't shown.

From Biocryst Pharmaceuticals Inc's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$2.6B
Institutions reporting
318
Shares held vs prior quarter
▲ 5.9%
Positions opened / closed
53 / 35

Top buyers and sellers, Q2 2026: 187 institutions bought and 121 sold ; the biggest buyer was Millennium Management LLC (+3.2M shares) and the biggest seller Royalty Pharma Sub-Manager, LLC (−3.8M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $239M 23.9M 9.1% ▲ 5.5%
RA Capital Management, L.P. $158M 15.8M 6.0% 0.0%
State Street Corp $152M 15.2M 5.8% ▲ 24.4%
Deerfield Management Company, L.P. $151M 15.1M 5.7% ▲ 0.4%
Vanguard Capital Management LLC $114M 11.4M 4.3% ▲ 2.1%
Vanguard Portfolio Management LLC $111M 11.1M 4.2% ▼ 0.9%
Tcg Crossover Management, LLC $110M 11.0M 4.2% 0.0%
Perceptive Advisors LLC $103M 10.3M 3.9% ▲ 38.7%
Jupiter Topco LLC $95.3M 9.5M 3.6% —
Vestal Point Capital, LP $83M 8.3M 3.1% ▲ 18.1%
Two Sigma Investments, LP $67.8M 6.8M 2.6% ▲ 6.0%
Geode Capital Management, LLC $62.5M 6.2M 2.4% ▲ 8.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Biocryst Pharmaceuticals Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $4.1M 10 trades by 4 insiders · 85% under pre-set plans
Net ▼ $4.1M net selling
Insider Date Trade Shares Price Value
Mckee Amy E Director May 18, 2026 Sell 11,180 $8.97 $100,285
Barnes Alane P Chief Legal Officer May 13, 2026 Sell pre-set plan 62,500 $9.54 $596,250
Heggie Theresa Director March 20, 2026 Sell 49,933 $10.11 $504,823
Barnes Alane P Chief Legal Officer March 16, 2026 Sell pre-set plan 150,000 $9.15 $1.4M
Barnes Alane P Chief Legal Officer December 22, 2025 Sell pre-set plan 21,773 $7.65 $166,563
Barnes Alane P Chief Legal Officer December 15, 2025 Sell pre-set plan 21,210 $7.65 $162,256
Barnes Alane P Chief Legal Officer December 3, 2025 Sell pre-set plan 19,770 $7.65 $151,240
Barnes Alane P Chief Legal Officer December 2, 2025 Sell pre-set plan 50,906 $7.21 $367,032
Barnes Alane P Chief Legal Officer December 1, 2025 Sell pre-set plan 91,004 $7.10 $646,128
Sanders Machelle Director November 13, 2025 Sell pre-set plan 9,600 $7.14 $68,544

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 5 trades and filings

In the last 12 months, 1 member of Congress disclosed 2 purchases and 0 sales of Biocryst Pharmaceuticals Inc shares.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded July 10, 2026, filed September 4, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded November 13, 2025, filed December 15, 2025
  • Josh Gottheimer(D-NJ 5):Purchase, $1,001 - $15,000, traded October 16, 2023, filed November 11, 2023

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 14, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 6, 2026
  • February 26, 2026
  • January 12, 2026
  • November 3, 2025
  • October 14, 2025

Recent SEC filings

Data status

When each part of this page on Biocryst Pharmaceuticals Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Biocryst Pharmaceuticals Inc in brief

What does Biocryst Pharmaceuticals Inc do?
Biocryst Pharmaceuticals Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Biocryst Pharmaceuticals Inc's stock ticker?
Biocryst Pharmaceuticals Inc trades under the ticker BCRX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Biocryst Pharmaceuticals Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Biocryst Pharmaceuticals Inc reported revenue of $941M, 68.7% higher than a year earlier, according to its SEC filings.
What is Biocryst Pharmaceuticals Inc's free cash flow?
Biocryst Pharmaceuticals Inc's free-cash-flow margin is 39.7% of revenue over the trailing twelve months, ranking 12 of the 176 biotechnology companies we cover.
Who are Biocryst Pharmaceuticals Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., RA Capital Management, L.P. and State Street Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Biocryst Pharmaceuticals Inc's market cap?
On November 2, 2026, Biocryst Pharmaceuticals Inc's market capitalisation was about $2B and net debt of $240M. Market figures come from third-party market data and may be delayed.
Who are Biocryst Pharmaceuticals Inc's competitors?
In our Biotechnology peer group, the companies closest to Biocryst Pharmaceuticals Inc are Bridgebio Pharma, Inc., Kiniksa Pharmaceuticals International, plc, Ionis Pharmaceuticals Inc, Legend Biotech Corp and Ascendis Pharma A/s. The side-by-side comparison below sets their revenue, margins and growth against Biocryst Pharmaceuticals Inc's.
Are insiders buying or selling Biocryst Pharmaceuticals Inc stock?
Over the last 12 months, Biocryst Pharmaceuticals Inc's directors and officers reported 0 open-market purchases and 10 sales on Form 4. The insider trading page charts every trade.
When is Biocryst Pharmaceuticals Inc's next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Biocryst Pharmaceuticals Inc announces its own schedule.